Contraception in perimenopause: a review of fecundity, fertility, and feasibility of contraceptives
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243626Keywords:
Contraception above 40, Contraception in older women, Hormone replacement therapy, Menopausal transition, Perimenopausal contraceptionAbstract
Menopausal transition warrants effective contraception despite reduced fecundity and fertility. The associated maternal and perinatal morbidities and mortality in women after 40 years has prompted women to choose safe and reliable contraceptives. Although the majority of women globally opt for sterilization; however, the observed trends in the last decade have seen an increase in the use of Long-acting reversible contraceptives. Combined hormonal contraceptives have been disrepute traditionally but the current literature remarks the use of CHC in selected populations. A literature search was conducted till December 2023 using the PubMed, Embase, SCOPUS databases and recommendations by various organizations using related search terms. This review highlights the various contraceptive options currently dispensed in the armamentarium for women above 40 years. The aim is to focus on the associated co-morbidities that can affect the contraceptive choices in this group and the contraceptive effects on the menopausal symptoms. This would guide the clinicians in prescribing the methods considering the complex requirements.
Metrics
References
Deatsman S, Vasilopoulos T, Rhoton-Vlasak A. Age and Fertility: A Study on Patient Awareness. JBRA Assist Reprod. 2016;20(3):99–106.
Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ Can Med Assoc J. 2013;16;185(7):565–73.
Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. Reprod Health. 2013;10(1):7.
Alspaugh A, Reibel MD, Im EO, Barroso J. “Since I’m a little bit more mature”: contraception and the arc of time for women in midlife. Womens Midlife Health. 2021;9;7(1):3.
Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas. 2013;1;76(3):235–42.
Devaraj K, Gausman J, Mishra R, Kumar A, Kim R, Subramanian SV. Trends in prevalence of unmet need for family planning in India: patterns of change across 36 States and Union Territories, 1993-2021. Reprod Health. 2024;9;21(1):48.
Van Heertum K, Liu J. Contraception and conception in Mid-life: a review of the current literature. Womens Midlife Health. 2017;16;3(1):3.
Konishi S, Kariya F, Hamasaki K, Takayasu L, Ohtsuki H. Fecundability and Sterility by Age: Estimates Using Time to Pregnancy Data of Japanese Couples Trying to Conceive Their First Child with and without Fertility Treatment. Int J Environ Res Public Health. 2021;20;18(10):5486.
Clark K, Westberg SM. Benefits of Levonorgestrel Intrauterine Device Use vs. Oral or Transdermal Progesterone for Postmenopausal Women Using Estrogen Containing Hormone Therapy. Innov Pharm. 2019;22;10(3):10-24.
Burgin J, Bailey JV. Factors affecting contraceptive choice in women over 40: a qualitative study. BMJ Open. 2022;22;12(11):64987.
Medical eligibility criteria for contraceptive use. Available at: https://www.who.int/publications. Accessed on 28 August 20204.
Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010;(29):1-44.
Statistics O for N. Contraception and Sexual Health. 2013. Available at: https://www.data.gov.uk/datase. ACCessed on 12 August 2024.
Black A, Yang Q, Wu Wen S, Lalonde AB, Guilbert E, Fisher W. Contraceptive use among Canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can. 2009;31(7):627-40.
Das M, Anand A, Hossain B, Ansari S. Inequalities in short-acting reversible, long-acting reversible and permanent contraception use among currently married women in India. BMC Public Health. 2022;28;22(1):1264.
Langton CR, Whitcomb BW, Purdue-Smithe AC, Sievert LL, Hankinson SE, Manson JE, et al. Association of oral contraceptives and tubal ligation with risk of early natural menopause. Hum Reprod Oxf Engl. 2021;2;36(7):1989–98.
Singh P, Singh KK, Singh P. Factors explaining the dominion status of female sterilization in India over the past two decades (1992-2016): A multilevel study. PLoS One. 2021;10;16(3):246530.
Eeckhaut MCW, Sweeney MM, Feng L. Desire for Sterilization Reversal Among U.S. Females: Increasing Inequalities by Educational Level. Perspect Sex Reprod Health. 2018;50(3):139–45.
Bansal A, Dwivedi LK. Sterilization regret in India: Is quality of care a matter of concern? Contracept Reprod Med. 2020;8;5(1):13.
Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015;94(1):86-94.
Bahamondes L, Fernandes A, Monteiro I, Bahamondes MV. Long-acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020;1;66:28–40.
Joshi R, Khadilkar S, Patel M. Global trends in use of long-acting reversible and permanent methods of contraception: Seeking a balance. Int J Gynecol Obstet. 2015;1;131:S60–3.
NHS England Digital. [cited 2024 Oct 8]. Sexual and Reproductive Health Services, England (Contraception) 2021/22. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/sexual-and-reproductive-health-services/2021-22
Products - Data Briefs - Number 327 - December 2018 [Internet]. 2022 [cited 2024 Oct 11]. Available from: https://www.cdc.gov/nchs/products/databriefs/db327.htm
FSRH Clinical Guideline: Contraception for Women Aged over 40 Years (August 2017, amended July 2023)-Faculty of Sexual and Reproductive Healthcare. Available at: https://www.fsrh.org/doc. Accessed on 21 August 2024.
Grandi G, Farulla A, Sileo FG, Facchinetti F. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677–86.
Joo JK, Shin JH, Lee JR, Kim MR. Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women. J Menopausal Med. 2021;27(2):49–57.
Abu Hashim H, Zayed A, Ghayaty E, El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013;24(2):128–34.
Fang F, Xu H, Wu L, Hu L, Liu Y, Li Y, et al. LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia. Am J Transl Res. 2021;15;13(5):5412-9.
Leone Roberti Maggiore U, Martinelli F, Dondi G, Bogani G, Chiappa V, Evangelista MT, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. J Gynecol Oncol. 2019;30(4):57.
Zhu H, Lei X, Feng J, Wang Y. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2012;17(6):402–14.
Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2014;24;2014(6):6033.
Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120(1):21-6.
Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–87.
Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95(5):736–44.
Gambacciani M, Monteleone P, Ciaponi M, Sacco A, Genazzani AR. Effects of oral contraceptives on bone mineral density. Treat Endocrinol. 2004;3(3):191-6.
Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;25:343.
Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11-6.
Roach REJ, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;27(8):11054.
Grandi G, Barra F, Ferrero S, Facchinetti F. Estradiol in non-oral hormonal contraception: a "long and winding road". Expert Rev Endocrinol Metab. 2019;14(3):153-5.
Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–39.
Reed S, Koro C, DiBello J, Becker K, Bauerfeind A, Franke C, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5 mg) and 17β-oestradiol (1.5 mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2021;26(6):439–46.
Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;1;78(3):218–25.
Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 2011;84(6):549–57.
Chiara Del Savio M, De Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–94.
Samson M, Porter N, Orekoya O, Hebert JR, Adams SA, Bennett CL, Steck SE. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016;155(1):3-12.
Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86(6):606–21.
Aged Over 40 | FSRH [Internet]. [cited 2024 Oct 11]. Available at: https://fsrh.org/Public. Accessed on 23 August 2024.
Beksinska ME, Smit JA, Kleinschmidt I, Farley TMM. Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception. SAMJ South Afr Med J. 2011;101(2):131–5.
Al-Hassan N. Guidance on contraception for women aged over 40 years. BMJ Sex Reprod Health. 2011;1;37(2):124–5.
FSRH CEU Statement: Mirena 8 years contraception. Available at: https://www.fsrh.org/Public/Public. Accessed on 16 August 2024.
Premalatha R, Tripathi MS. A Study on the Reversal of Sterilisation in Women Over Two Decades. J Obstet Gynaecol India. 2012;62(1):62–7.
Bansal A, Dwivedi LK, Ali B. The trends of female sterilization in India: an age period cohort analysis approach. BMC Womens Health. 2022;5;22:272.
Singh M, Shekhar C, Shri N. Changes in age at last birth and its determinants in India. Sci Rep. 2023;27;13:10450.
Huang M, Gutiérrez-Sacristán A, Janiak E, Young K, Starosta A, Blanton K, et al. Contraceptive content shared on social media: an analysis of Twitter. Contracept Reprod Med. 2024;7:5-9.
